Cargando…
Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
Biomarker in metastatic castration resistant prostate cancer (mCRPC) treatment are rare. We aimed to compare the clinical value of circulating tumor cells (CTCs) and androgen receptor splice variant 7 (AR-V7) as biomarker in mCRPC patients undergoing androgen receptor-targeted agent (ARTA) treatment...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279395/ https://www.ncbi.nlm.nih.gov/pubmed/35831403 http://dx.doi.org/10.1038/s41598-022-16094-6 |
_version_ | 1784746388388577280 |
---|---|
author | Schlack, Katrin Seitzer, Konstantin Wüstmann, Neele Humberg, Verena Grundmann, Norbert Steinestel, Julie Tiedje, Dorothee Rahbar, Kambiz Krabbe, Laura-Maria Bögemann, Martin Schrader, Andres J. Bernemann, Christof |
author_facet | Schlack, Katrin Seitzer, Konstantin Wüstmann, Neele Humberg, Verena Grundmann, Norbert Steinestel, Julie Tiedje, Dorothee Rahbar, Kambiz Krabbe, Laura-Maria Bögemann, Martin Schrader, Andres J. Bernemann, Christof |
author_sort | Schlack, Katrin |
collection | PubMed |
description | Biomarker in metastatic castration resistant prostate cancer (mCRPC) treatment are rare. We aimed to compare the clinical value of circulating tumor cells (CTCs) and androgen receptor splice variant 7 (AR-V7) as biomarker in mCRPC patients undergoing androgen receptor-targeted agent (ARTA) treatment. Overall cohort (65 patients) was stratified regarding either CTC or AR-V7 status followed by further sub-stratification of the respective other marker. Subsequently, prostate specific antigen (PSA) response, progression free survival (PFS) and overall survival (OS)) of subgroups was compared. CTCs and AR-V7 were detected in 54 (83%) and 33 (61%) patients, respectively. All AR-V7 + were CTC +. We detected PSA response in all subgroups. For PFS and OS, biomarker stratification revealed differences between all subgroups. Interestingly, no significant differences of AR-V7 transcript copy numbers were detected between responding and non-responding patients. Additionally, multivariable analysis revealed no independent prognostic value of AR-V7 positivity. Both biomarkers show clinical value in prognosticating clinical outcome. Nonetheless, AR-V7 stratification underestimates the heterogenous subgroup of CTC − and CTC + patient, the latter requiring more intense clinical surveillance. Additionally, AR-V7 level does not correlate with clinical response. Thus, the value of AR-V7 as a clinical biomarker must be considered skeptically. |
format | Online Article Text |
id | pubmed-9279395 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-92793952022-07-15 Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients Schlack, Katrin Seitzer, Konstantin Wüstmann, Neele Humberg, Verena Grundmann, Norbert Steinestel, Julie Tiedje, Dorothee Rahbar, Kambiz Krabbe, Laura-Maria Bögemann, Martin Schrader, Andres J. Bernemann, Christof Sci Rep Article Biomarker in metastatic castration resistant prostate cancer (mCRPC) treatment are rare. We aimed to compare the clinical value of circulating tumor cells (CTCs) and androgen receptor splice variant 7 (AR-V7) as biomarker in mCRPC patients undergoing androgen receptor-targeted agent (ARTA) treatment. Overall cohort (65 patients) was stratified regarding either CTC or AR-V7 status followed by further sub-stratification of the respective other marker. Subsequently, prostate specific antigen (PSA) response, progression free survival (PFS) and overall survival (OS)) of subgroups was compared. CTCs and AR-V7 were detected in 54 (83%) and 33 (61%) patients, respectively. All AR-V7 + were CTC +. We detected PSA response in all subgroups. For PFS and OS, biomarker stratification revealed differences between all subgroups. Interestingly, no significant differences of AR-V7 transcript copy numbers were detected between responding and non-responding patients. Additionally, multivariable analysis revealed no independent prognostic value of AR-V7 positivity. Both biomarkers show clinical value in prognosticating clinical outcome. Nonetheless, AR-V7 stratification underestimates the heterogenous subgroup of CTC − and CTC + patient, the latter requiring more intense clinical surveillance. Additionally, AR-V7 level does not correlate with clinical response. Thus, the value of AR-V7 as a clinical biomarker must be considered skeptically. Nature Publishing Group UK 2022-07-13 /pmc/articles/PMC9279395/ /pubmed/35831403 http://dx.doi.org/10.1038/s41598-022-16094-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Schlack, Katrin Seitzer, Konstantin Wüstmann, Neele Humberg, Verena Grundmann, Norbert Steinestel, Julie Tiedje, Dorothee Rahbar, Kambiz Krabbe, Laura-Maria Bögemann, Martin Schrader, Andres J. Bernemann, Christof Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients |
title | Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients |
title_full | Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients |
title_fullStr | Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients |
title_full_unstemmed | Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients |
title_short | Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients |
title_sort | comparison of circulating tumor cells and ar-v7 as clinical biomarker in metastatic castration-resistant prostate cancer patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279395/ https://www.ncbi.nlm.nih.gov/pubmed/35831403 http://dx.doi.org/10.1038/s41598-022-16094-6 |
work_keys_str_mv | AT schlackkatrin comparisonofcirculatingtumorcellsandarv7asclinicalbiomarkerinmetastaticcastrationresistantprostatecancerpatients AT seitzerkonstantin comparisonofcirculatingtumorcellsandarv7asclinicalbiomarkerinmetastaticcastrationresistantprostatecancerpatients AT wustmannneele comparisonofcirculatingtumorcellsandarv7asclinicalbiomarkerinmetastaticcastrationresistantprostatecancerpatients AT humbergverena comparisonofcirculatingtumorcellsandarv7asclinicalbiomarkerinmetastaticcastrationresistantprostatecancerpatients AT grundmannnorbert comparisonofcirculatingtumorcellsandarv7asclinicalbiomarkerinmetastaticcastrationresistantprostatecancerpatients AT steinesteljulie comparisonofcirculatingtumorcellsandarv7asclinicalbiomarkerinmetastaticcastrationresistantprostatecancerpatients AT tiedjedorothee comparisonofcirculatingtumorcellsandarv7asclinicalbiomarkerinmetastaticcastrationresistantprostatecancerpatients AT rahbarkambiz comparisonofcirculatingtumorcellsandarv7asclinicalbiomarkerinmetastaticcastrationresistantprostatecancerpatients AT krabbelauramaria comparisonofcirculatingtumorcellsandarv7asclinicalbiomarkerinmetastaticcastrationresistantprostatecancerpatients AT bogemannmartin comparisonofcirculatingtumorcellsandarv7asclinicalbiomarkerinmetastaticcastrationresistantprostatecancerpatients AT schraderandresj comparisonofcirculatingtumorcellsandarv7asclinicalbiomarkerinmetastaticcastrationresistantprostatecancerpatients AT bernemannchristof comparisonofcirculatingtumorcellsandarv7asclinicalbiomarkerinmetastaticcastrationresistantprostatecancerpatients |